Search Results

RELIEF THERAPEUTICS Holding SA announces the results of its annual general meeting (AGM) of shareholders, which took place in Geneva today.

RELIEF THERAPEUTICS Holding SA announces the results of the extraordinary general meeting of shareholders, which took place in Geneva , Friday, April 26, 2024.

ExcellGene SA proudly announces its strategic collaboration with Cytovance Biologics, a renowned Contract Development and Manufacturing Organization based in the USA.

Stryker (NYSE: SYK), a leading global medical technology company, announced today that it has completed the previously announced acquisition of SERF SAS, a France -based joint replacement company, from Menix.

Linnea SA, a leading global Active Pharmaceutical Ingredients manufacturer with over 40 years of experience and a long-term presence in the Latam area, is pleased to announce the start of a strategic partnership with the Universidade Estadual de Campinas, a prestigious public research university in the state of São Paulo, Brazil.

In the presence of the esteemed Christopher Skeete, Minister for the Economy, and Christine Poirier, Laval City Councillor, , Corealis Pharma Inc. proudly inaugurates the expansion of its facilities nestled in the heart of Laval’s Biotech City.

Finacity Corporation announced that it has successfully launched a trade receivables securitization for Laboratorios Sanfer, S.A. de C.V.

Novadip Biosciences SA announced that the first US patient has been implanted with its investigational tissue regeneration product, NVD-003, in its Phase 1b/2a clinical trial in Congenital Pseudarthrosis of Tibia, a rare pediatric bone condition.

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announced the results of a follow-up analysis of a Phase 3 study evaluating a booster dose of ARCT-154 , the world’s first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine, compared to a conventional mRNA COVID-19 vaccine.